Magenta Therapeutics: David Nichols
Magenta Therapeutics, a clinical-stage biotech based in Cambridge, Massachusetts, with a focus on stem cell transplants, has appointed David Nichols as Chief Technical Officer.
Nichols will serve as a member of Magenta’s Executive Team and will lead all of the company’s CMC activities from early development through commercial products across the company’s pipeline, including driving strategic initiatives to improve efficiency, consistency, compliance and risk mitigation for Magenta’s antibody drug conjugate, cell therapy, and peptide manufacturing processes.
Nichols comes to Magenta with more than 25 years of experience in biologics process development across the life sciences industry. Most recently, Mr. Nichols served as Senior Vice President of Kiniksa Pharmaceuticals, where he was responsible for all process development and internal and external GMP manufacturing.
His past positions have included Head of CMC Biologicals Drug Substances at Tesaro Pharmaceuticals; Senior Director of Process Development at Operations at Teva Pharmaceuticals and Senior Director, CMC Integration at Shire Pharmaceuticals.
Nichols holds an MBA from Northeastern University and a Masters in Biochemistry from the University of New Hampshire.
